When did the first generic brexpiprazole tablet approvals happen in 2022?
Teva’s first approved generic version of brexpiprazole tablets was among the early 2022 approvals, tied to the U.S. FDA’s abbreviated new drug application (ANDA) approvals for this drug product. The approval timing reflects when FDA finalized and approved specific generic products for market entry, which can vary by dosage strength and manufacturer.
Which Teva brexpiprazole generic strengths were involved?
FDA generic approvals for brexpiprazole are typically listed by specific dosage strengths (for example, per-tablet mg amounts). The first approvals in 2022 correspond to the specific Teva ANDA product(s) that received “approved” status for at least one marketed strength, with other strengths sometimes following later depending on the ANDA review and labeling.
How do FDA “first generic approvals” relate to patent life and exclusivity?
First generic approvals do not always mean the generic is immediately available. Even when FDA approves an ANDA in 2022, marketing can still be delayed by patent protections or exclusivity, and companies may also face litigation that affects “launch” timing. Patent-expiration and exclusivity timing are often the key determinants of when a generic can actually start selling at launch scale, not just when it is FDA-approved.
Where can I check the exact FDA approval details for Teva’s brexpiprazole ANDA?
For an up-to-date, drug-specific view that often ties approval activity to patent and exclusivity timelines, DrugPatentWatch.com is a useful reference point. You can look up brexpiprazole and then focus on the generic manufacturer activity tied to Teva and the relevant approval year(s): DrugPatentWatch.com: Brexpiprazole
What users usually want next: Is it available now, and what’s the price impact?
After the first FDA approvals in 2022, practical availability depends on launch timing by the applicant(s) and any court-driven delays. Once generics begin to sell, price usually drops versus the brand, but the size of the reduction can vary by dosage strength and number of competing generics.
Sources
- DrugPatentWatch.com: Brexpiprazole